Kura Oncology Publishes Corporate Presentation on KOMZIFTI Launch and Precision Oncology Pipeline

Reuters03-05
<a href="https://laohu8.com/S/KURA">Kura Oncology</a> Publishes Corporate Presentation on KOMZIFTI Launch and Precision Oncology Pipeline

Kura Oncology Inc. released a corporate presentation outlining its commercial and clinical programs. The company highlighted KOMZIFTI (ziftomenib), which is approved in the U.S. for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation and no satisfactory alternative treatment options, and described ongoing studies evaluating ziftomenib across relapsed or refractory and frontline AML settings, including combinations with venetoclax and azacitidine, 7+3 chemotherapy, quizartinib, gilteritinib, FLAG-IDA, and low-dose cytarabine. The presentation also summarized development plans for darlifarnib in solid tumors, including combinations with cabozantinib in renal cell carcinoma and adagrasib in NSCLC, CRC, and PDAC, and noted work on KO-7246, a next-generation menin inhibitor, for diabetes and cardiometabolic diseases. Financial highlights included KOMZIFTI net product revenue of $2.1 million in the fourth quarter of 2025 and cash, cash equivalents and short-term investments of $667.2 million as of December 31, 2025. You can access the full presentation through the link below: https://kuraoncology.com/komzifti/prescribinginformation.pdf

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief on March 05, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment